Recent FDA Guidance on Compounded GLP-1s: In October 2023, the FDA issued warnings about compounded GLP-1 medications, specifically cautioning patients to ensure theyre receiving semaglutide (the actual FDA-approved ingredient) rather than semaglutide salts, which have different properties
Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment
"Compounded copies of these FDA-approved drugs are not a long-term therapy for these patients." End the shortages, end compounding The battle over compounding has intensified in recent months, taking twists and turns
Karacabeyli and Lacaille reviewed GLP-1 therapy use in inflammatory arthritis in a 2024 paper published in the Journal of Clinical Rheumatology
Plan for the Week, Not Just One Cookout Consistency over time matters more than any one meal
The boxed warning for thyroid Ccell tumors is based on rodent carcinogenicity studies showing dose and durationdependent Ccell tumor formation at exposures relevant to human dosing
